INTRALASE FS2
Report
- Report Number
- 3006695864-2018-00075
- Event Type
- Injury
- Date Received
- January 12, 2018
- Date of Event
- December 27, 2017
- Report Date
- March 6, 2018
- Manufacturer
- ABBOTT MEDICAL OPTICS
- Product Code
- HNO
- PMA / PMN Number
- K060372
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- WI, US
- Reporter Occupation
- PHYSICIAN
Narratives
(B)(4). ALL PERTINENT INFORMATION AVAILABLE TO ABBOTT MEDICAL OPTICS HAS BEEN SUBMITTED.
DEVICE EVALUATION: A REVIEW OF THE RECORDS RELATED TO THE DEVICE THAT INCLUDED LABELING, MANUALS, TRENDING, AND RISK DOCUMENTATION WAS PERFORMED. THE TREND REVIEW SHOWS THAT THERE IS NOT SIGNIFICANT CHANGE OVER HISTORICAL COMPLAINT LIMITS AND NO RECOGNIZABLE ADVERSE TREND. THE RISKS AND MITIGATIONS ASSOCIATED WITH THE COMPLAINT ISSUE ARE IDENTIFIED IN EXISTING RISK DOCUMENTS AND NO NEW RISKS WERE IDENTIFIED AS PART OF THIS INVESTIGATION. THERE WAS NO PRODUCT DEFICIENCY IDENTIFIED. ALL PERTINENT INFORMATION AVAILABLE TO JOHNSON & JOHNSON SURGICAL VISION, INC. HAS BEEN SUBMITTED.
THE CLINIC REPORTED THAT A LASER VISION CORRECTION PATIENT HAD SURGERY ON (B)(6) 2017 AND PRESENTED ON (B)(6) 2017 WITH EPITHELIAL INGROWTH IN THE RIGHT EYE THAT WAS DISCOVERED DURING SLIT LAMP EXAM. A FLAP LIFT AND RINSE WAS SCHEDULED. IT WAS STATED THAT THE PATIENT HAD NO LOSS OF BEST CORRECTED VISUAL ACUITY (BCVA). THE PATIENT HAD NO COMPLAINTS. PATIENT REPORTED SYMPTOMS ARE NOT INTERFERING WITH DAILY ACTIVITIES. BCVA FROM (B)(6) 2017: RIGHT EYE PRE-OP 20/20 .75 X -1.25 X 108, LEFT EYE PRE-OP 20/20 .75 X -1.50 X 75. BCVA FROM (B)(6) 2017: RIGHT EYE POST-OP 20/20 .50 X -.75 X 25, LEFT EYE POST-OP 20/20 .00 X -.75 X 79. THIS REPORT IS FOR THE INTRALASE SYSTEM. A SEPARATE REPORT IS BEING SUBMITTED FOR THE VISX LASER.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 29705 | INTRALASE FS2 | FEMTOSECOND LASER | HNO | ABBOTT MEDICAL OPTICS | 20003D |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 33 YR | Required Intervention | VISX 5475 |